Luminary's Pipeline
Non-viral Cell Therapies
- Luminary is developing a broad pipeline of non-viral cell therapies via in-licensed advancements from notable academic institutions and internally developed IP.
- Our product pipeline will focus on underserved cancers and autoimmune disorders.
- We are aggressively pursuing our BAFF CAR-T therapy planning to file an IND with the FDA in Q4 2021
| Program | Type | Indication | Research | Preclinical | Phase 1 | Phase 2 & 3 |
|---|---|---|---|---|---|---|
| LMY-920 BAFF |
CAR-T |
B-cell Malignancies
|
||||
|
Autoimmune Disorders
|
||||||
| LMY-232 Multiple Targets |
Universal Receptor |
Solid Tumors &
Autoimmune Disorders |
Targeting multiple B cell markers on tumor and inflammatory cells
LMY-920’s BAFF target has the potential to preserve early B cells
Depiction of our proprietary B cell activating factor (BAFF) directed third-generation chimeric antigen receptor (CAR). LMY-920’s BAFF targets multiple B cell markers on tumor and inflammatory cells including the BAFF receptor (BAFF-R), BCMA, and TACI.
